This article was originally published in The Gray Sheet
Cell therapy joint venture, Nexell Therapeutics, will be headed by William McIntosh, former executive vice president of business development and chief financial officer at VimRx. Nexell, which formerly was Baxter's Immunotherapy Division, is developing and marketing cell therapies for cancer and other life-threatening diseases. The firm's lead products are the Isolex 300 and Isolex 300I cell selection systems. Although FDA's Biological Response Modifiers Advisory Committee did not take a formal vote on the Isolex 300's premarket approval application, the panel did agree that study data demonstrated efficacy ("The Gray Sheet" July 28, 1997, p. 8)...
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.